Broker's take: DBS upgrades Riverstone to 'buy' as valuation turns attractive
DBS Group Research has upgraded Riverstone Holdings to "buy" from "hold" and lowered its target price to S$1.85 from S$2.03.
This comes as the Malaysian glove marker's valuation becomes attractive again after share price correction on vaccine news, DBS said in a research note on Monday.
DBS analyst Ling Lee Keng said Riverstone is now trading at an attractive fiscal 2021 price-to-earnings (PE) ratio of 7.3 times, near the minus-one standard deviation of its five-year PE average.
"Furthermore, we also expect a bumper dividend for FY2020," she added.
The research team expects a firm average selling price on the back of strong demand and tight supply. Order visibility has been further extended to December 2021.
Even with the Covid-19 vaccine's availability, demand is not expected to taper off immediately as hygiene is still a key concern, Ms Ling said. Moreover, the mass availability of vaccines will take time, and the new Covid-19 strain raises risk.
GET BT IN YOUR INBOX DAILY
Start and end each day with the latest news stories and analyses delivered straight to your inbox.
Shares of mainboard-listed Riverstone were trading S$0.02 or 1.5 per cent lower at S$1.33 as at 10.16am on Monday.
KEYWORDS IN THIS ARTICLE
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Companies & Markets
China’s top airlines improve balance sheet in Q1; outlook positive for May Day
Stablecoin issuer Tether invests US$200 million in brain-computer interface company
Yahoo to lay off staff in Singapore as it shifts to content curation
US: Wall St opens higher on megacap strength, Fed verdict awaited
IReit Global occupancy rate grows to 91.5% in Q1
Yen surges against US dollar on suspected intervention